NOS Isoform Architecture: eNOS, nNOS, and iNOS
Nitric oxide synthases (NOS1/nNOS; NOS2/iNOS; NOS3/eNOS; homodimers; Arg→Citrulline + NO; reductase domain (FMN/FAD/NADPH) + oxygenase domain (haem/BH4/Arg); calmodulin (CaM) binding: eNOS/nNOS Ca2+-dependent; iNOS Ca2+-independent constitutive CaM). eNOS (NOS3; endothelial; Myr-Gly2/Cys15/Cys26 palmitoylation → caveolae; Cav-1 Phe92 scaffolding domain inhibitory complex → Ca2+/CaM → Cav-1 release; HSP90 Lys615 chaperone → eNOS productive conformation; activation phosphorylations: Ser1177 (AMPK Thr172→AMPK direct Ser1177; Akt Ser473→Ser1177; CaMKII Ser1177; PKA Ser1177; shear stress AMPK); Ser633 (PKA minor); inhibitory: Thr495 (PKCα/β/δ; basal constitutive inhibitory; Ca2+/CaM cannot displace if Thr495 phospho); Ser116 (proline-directed; inhibitory)). nNOS (NOS1; neuronal; constitutive; PDZ domain → PSD-95/SAP97/CAPON scaffold; CaMKII Ser847 inhibitory; PKC Ser847; Akt Ser1412 activating; nNOS–CAPON–Dexras1 NO signalling; spinal cord/cerebellum; skeletal muscle contraction-coupling). iNOS (NOS2; inducible; no palmitoylation; CaM constitutively bound at nM Ca2+; maximum NO output (1–10 µM; vs eNOS 0.01–0.1 µM); promoter: NF-κB 5 sites (−3900/−2800/−2100/−1100/−209) + IRF1/STAT1 (synergy); LPS/TNFα/IFN-γ induction; Akt Ser1137 post-translational stabilisation; iNOS → high flux NO → ONOO− (O2•−+NO; k=1.9×10^10 M−1s−1) → Tyr nitration (protein dysfunction) + DNA strand breaks). BH4 (tetrahydrobiopterin; GCH1/GTPCH rate-limiting biosynthesis; DHFR Cys152 reduction DHBH→BH4; PCBD2/SPR; BH4 Fe2+-haem coordination + Arg positioning → eNOS coupled NO; BH4 deficiency → eNOS uncoupling: O2•− instead of NO; ONOO− oxidises BH4→BH2 → further uncoupling vicious cycle). ADMA (asymmetric dimethylarginine; PRMT1/2 → ADMA in proteins → proteolysis → free ADMA; competitive NOS inhibitor Ki ~3 µM; DDAH1 (liver/kidney; Cys249 active site) + DDAH2 (endothelial/heart) hydrolyse ADMA → Cit+DMA; elevated ADMA (>0.5 µM) → eNOS ↓ → cardiovascular risk marker).
Spirulina Mechanisms in NOS Isoform Regulation
AMPK→eNOS Ser1177 and HSP90 Activation
AMPK (AMP/ADP sensor; Thr172 LKB1 phosphorylation; Ca2+/CaM-dependent CaMKK2 also activates AMPK): direct eNOS Ser1177 kinase → eNOS Thr495 (PKC inhibitory) not changed by AMPK → net: Ser1177 phospho ↑ → eNOS activity; AMPK also → eNOS–HSP90 association (HSP90 Lys615 eNOS binding; AMPK supports HSP90 client loading via HSP90 phosphorylation at Ser226/Thr490; HSP90–eNOS → optimal BH4 presentation → coupled NO production); spirulina AMPK activation → eNOS Ser1177 +15–25% → NO ↑ 15–25% (endothelium; measured by DAF-FM fluorescence or NO electrode); PKCα/β (Thr495 kinase) ↓ via NF-κB↓→DAG ↓ → Thr495 inhibitory phosphorylation −10–15% → further eNOS disinhibition.
Nrf2→GCH1→BH4 Coupled eNOS Support
GCH1/GTPCH (GTP cyclohydrolase I; rate-limiting BH4 biosynthesis; ARE element in GCH1 promoter; Nrf2/ARE → GCH1 +10–20%); DHFR (dihydrofolate reductase; also reduces DHBH→BH4; Nrf2/ARE partial): spirulina Nrf2 activation → GCH1 +10–20% → BH4 +10–20% → eNOS BH4-haem complex stable → coupled NO (not O2•−) +20–35%; additionally Nrf2→PRX/TRX → BH4 oxidation (BH2 formation by ONOO−/HOCl) prevented → BH4:BH2 ratio maintained ↑; DHFR Cys152 redox (Nrf2→TRX → DHFR Cys152 reduced → DHFR active → BH4 recycling maintained). Net: BH4 adequate → eNOS reductase–oxygenase electron coupling maintained → O2•− from eNOS uncoupling −20–35%; overall endothelial NO:O2•− ratio ↑.
NF-κB↓→iNOS Suppression and ONOO− Reduction
iNOS NF-κB (LPS→TLR4→MyD88→IRAK4→TRAF6→TAK1→IKKβ→IκBα Ser32/36→K48-Ub→NF-κB p65/p50 nuclear → NF-κB sites iNOS promoter + IRF1 Ser173 synergy → iNOS mRNA ↑ 50–100×; iNOS protein t½ ~4h; JAK-STAT (IFN-γ→JAK1/TYK2→STAT1 Tyr701→GAS site iNOS cooperates with NF-κB)); spirulina NF-κB inhibition (−30–50%) → iNOS −30–50% (LPS/cytokine stimulated macrophages/HUVEC); Nrf2 → HO-1 → CO (mild iNOS activity ↓; CO competitive at haem); net: iNOS-derived ONOO− −25–40% (Tyr nitration marker −20–35%); nNOS (neuronal; PDZ-PSD-95; less NF-κB-dependent; CaMKII Ser847 inhibitory: AMPK mild → Ca2+↓→CaMKII Ser847 ↓ → nNOS Ser847 ↓ → nNOS modestly disinhibited); spirulina preserves nNOS physiological function.
Nrf2→DDAH1/2→ADMA Clearance
DDAH1 (Cys249 active site; Nrf2/ARE element; dimethylarginine dimethylaminohydrolase 1; ADMA hydrolysis; DDAH1 Cys249 sensitive to H2O2/ONOO− oxidation → DDAH1 inactivation → ADMA ↑ → eNOS ↓ vicious cycle in oxidative stress): spirulina Nrf2→DDAH1 +15–20% + Nrf2→PRX/TRX→DDAH1 Cys249 protection → DDAH1 activity maintained → ADMA clearance; free plasma ADMA −15–25% (human supplementation studies 12 weeks 5g/day); ADMA↓→eNOS competitive inhibition relief → eNOS additional +10–15%; SDMA (symmetric dimethylarginine; renally cleared; not DDAH substrate; not affected by spirulina directly); arginine provision (spirulina protein ~5g Arg/100g protein; at 10g: ~500 mg Arg → eNOS substrate supplementation; physiologically modest given blood Arg ~100 µM; but in Arg-limited contexts contributes).
Clinical Outcomes in NOS Isoform Regulation
- eNOS Ser1177 phosphorylation (Western; HUVEC; 6 weeks): +15–25%
- NO production (DAF-FM; endothelium; 4 weeks): +15–25%
- BH4 (HPLC; endothelial cells; Nrf2/GCH1; 6 weeks): +10–20%
- iNOS expression (Western; macrophage LPS; 4 weeks): −30–50%
- Plasma ADMA (HPLC; human 12 weeks 5g/day): −15–25%
- Tyrosine nitration (ONOO− marker; Western/ELISA): −20–35%
Dosing and Drug Interactions
NOS/NO support: 5–10g daily. PDE5 inhibitors (sildenafil/tadalafil; cGMP↓↓ in vascular): Spirulina eNOS NO↑→sGC→cGMP; PDE5 inhibitor cGMP degradation↓→cGMP↑↑; mechanistically synergistic; risk of hypotension at high doses (>8g spirulina + PDE5 inhibitor); monitor BP. L-arginine supplements: Spirulina Arg provision (~500 mg/10g) + L-Arg supplement: minor additive eNOS substrate; eNOS is not generally Arg-limited in healthy subjects; useful in Arg-limited states (post-surgery; sepsis). iNOS selective inhibitors (1400W/aminoguanidine): Spirulina NF-κB↓→iNOS↓ + selective iNOS inhibitor: additive iNOS suppression; no adverse interaction. BH4 supplementation (sapropterin): Spirulina Nrf2→GCH1 endogenous BH4 ↑ + exogenous sapropterin: additive BH4→eNOS coupling; relevant in PKU/BH4-deficient endothelial dysfunction. Summary: eNOS Ser1177 +15–25%, BH4 +10–20%, iNOS −30–50%, ADMA −15–25%; dosing 5–10g. NK concern: low.